Division of Hematology and Oncology

New therapeutic strategy for leukemia syndrome

Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy.

New Clinician Spotlight: Laura Kennedy

Laura Kennedy, MD, PhD, has joined Vanderbilt University Medical Center from the University of Washington School of Medicine/Fred Hutchinson Cancer Research Center in Seattle where she was acting instructor and research associate.

Benjamin Brown, left, Jens Meiler, PhD, Zhenfang Du, PhD, and colleagues are studying the functional consequences of genetic mutations and how those changes can drive cancerous growth.

Personalized Structural Biology aids cancer treatment decisions

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

New Clinician Spotlight: Robert Ramirez

Robert Ramirez, DO, a thoracic and neuroendocrine oncologist, has joined Vanderbilt-Ingram Cancer Center after practicing at Ochsner Medical Center and Louisiana State University (LSU) Health Science Center in New Orleans.

Prostate cancer microenvironment

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

EGFR Resisters/LUNGevity fund lung cancer research

Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.

1 4 5 6 7 8 13